All In Biotech

Drug Trial Radar · NCT04464733

Safety, Tolerability, Pharmacokinetics(PK), Pharmacodynamics(PD) and Food Effect of HRS9950 in Healthy and CHB Subjects

A Phase I Study to Evaluate the Safety, Tolerability and PK, PD of Oral HRS9950 in Healthy Subjects With Single or Multiple Dose and Chronic Hepatitis B Patients With Multiple Dose, and Food Effects of HRS9950 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Nov 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 146 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

146

Actual

Start

Jul 20, 2020

Primary completion

May 30, 2023

Study completion May 30, 2023

Sponsor

Sponsor type
Industry
First posted
Jul 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study is a randomized, Double-Blind, Placebo-Controlled study to evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics and food effect of HRS9950. The study will be conducted in three parts sequentially: Part 1, evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics of single doses and multiple dose of HRS9950 tablet in healthy subjects. Part 1 will consist of 84 healthy subjects, 8 groups.There will be 14 subjects in 0.75mg dose group,10 subjects in each other dose group . Part 2, evaluate food effect of HRS9950 in healthy subjects. Part 2 will consist of 14 healthy subjects, 1 group (one of groups in Part 1). Part 3, evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics of multiple doses of HRS9950 tablet in naive and treatment-experienced chronic hepatitis B (CHB) patients. Part 3 will consist of 60 CHB patients, 1 group for naive patients and 5 groups for treatment-experienced patients.

Conditions

  • Chronic Hepatitis b

Interventions

  • HRS9950Drug

    HRS9950

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence and severity of treatment-related adverse events as assessed by CTCAE v5.0Time frame: 8 DAYS for Group A-M; 29 DAYS for Group F; 50 DAYS for Group G-O
  2. Maximum Plasma Concentration [Cmax]Time frame: 0-48 hours after each dose for Group A-E、K-M;Group F- J、N、O at Day 1 and Day 22
  3. Area under the concentration time curve [AUC]Time frame: 0-48 hours after each dose for Group A-E、K-M;Group F- J、N、O at Day 1 and Day 22
  4. Time to maximum plasma concentration [Tmax]Time frame: 0-48 hours after each dose for Group A-E、K-M;Group F- J、N、O at Day 1 and Day 22
  5. Apparent clearance [CL/F]Time frame: 0-48 hours after each dose for Group A-E、K-M;Group F- J、N、O at Day 22
  6. Half-time [t1/2]Time frame: 0-48 hours after each dose for Group A-E、K-M;Group F- J、N、O at Day 22
  7. Apparent volume of distribution [Vz/F(Vd)]Time frame: 0-48 hours after each dose for Group A-E、K-M;Group F- J、N、O at Day 22
  8. Mean residence time [MRT]Time frame: 0-48 hours after each dose for Group A-E、K-M;Group F- J、N、O at Day 22
  9. The concentration of IL-12p40 in the serumTime frame: 0-48 hours after each dose for Group A-E、G-O

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Youan Hospital,Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.